EASTERN COOPERATIVE ONCOLOGY GROUP

贝斯以色列女执事医疗中心（BIDMC）是1996年贝斯以色列和新英格兰女执事医院合并而成的，这两个医院是朗伍德医疗区的两个邻居和主要的哈佛医学院机构。BIDMC的教职员工，加上新招募的长期驻扎在波士顿的ECOG成员，现在包括一群杰出的临床癌症研究人员。作为CareGroup网络的主要高等教育/学术资源，BIDMC拥有一个自然和现成的ECOG网络，以增加其在癌症治疗以及临床和基础科学研究方面的卓越传统。BIDMC拥有全国公认的特殊专业中心，包括放射联合中心（JCRT）、肝脏和其他实体器官移植、艾滋病和相关恶性肿瘤、乳腺癌/妇女健康、恶性黑色素瘤、医学信息学和临床试验方法学、细胞因子和生物治疗。哈佛医学院（h.i.m）位于附近提供了优秀的研究科学家和实验室为基础的合作小组转化研究组件。BIDMC于1997年5月作为范德比尔特大学的附属机构加入ECOG。从1997年5月到1997年10月，作为附属机构，BIDMC进入了36个病例。基于这一强有力的活动和1997年9月令人满意的实地考察，BIDMC于1997年10月被授予主要会员机构地位，并于1998年1月获准申请ECOG核心赠款。从1997年10月到1997年12月，BIDMC作为主要机构，纳入了19例患者进行ECOG研究。到目前为止，1998年BIDMC累计有33名患者，使1997年5月至1998年5月的累计患者总数达到88名。我们致力于在ECOG指定的癌症预防、诊断和治疗领域开展实验室和临床研究，并在过去证明了高水平的患者累积，并有可能在未来做出更大的贡献，群体科学和患者登记。

Beth Israel Deaconess Medical Center (BIDMC) resulted from the 1996 merger of the Beth Israel and New England Deaconess Hospitals, two neighbors and major Harvard Medical School institutions in the Longwood Medical Area. The BIDMC faculty, together with newly recruited long-time Boston-based ECOG members now includes an exceptional group of committed clinical cancer researchers. Serving as the principal tertiary/academic resources of the CareGroup Network, BIDMC has a natural and ready-made ECOG network to add to its long tradition of excellence in cancer care as well as both clinical and basic science research. BIDMC is home to nationally recognized centers of special expertise including the Joint Center for Radiation (JCRT), liver and other solid-organ transplantation, AIDS and related malignancies, breast cancer/women's health, malignant melanoma, medical informatics and clinical trials methodology, cytokine and biologic therapy. The Harvard Institute of Medicine (H.I.M.) Located nearby provides outstanding research scientists and laboratory-based components for cooperative group translational research. BIDMC joined ECOG as an affiliate of Vanderbilt University in May 1997. From May '97-October '97, as an affiliate, BIDMC entered 36 cases. Based on this strong activity and a fully satisfactory site visit in September '97, BIDMC was granted Main Member Institution status in October '97 and approved to apply for an ECOG Core Grant in January 1998. From October '97 to December '97, as a main institution, BIDMC enrolled 19 patients to ECOG studies. To date, in 1998 BIDMC has accrued 33 patients, making the total accrual for May '97 to May '98 equal to 88 patients. We are committed to conducting laboratory and clinical research in the ECOG specified areas of cancer prevention, diagnosis, and treatment and have demonstrated high levels of patient accrual in the past and have the potential for even greater contributions, group science, and patient enrollment in the future.